PRAKTIChESKIE ASPEKTY NAZNAChENIYa ZAMESTITEL'NOY GORMONAL'NOY TERAPII TESTOSTERONOM PRI VOZRASTNOM ANDROGENNOM DEFITsITE U MUZhChIN


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Full Text

Restricted Access

About the authors

I. A. Korneev

Email: iakorneyev@yandex.ru

References

  1. Brinkmann A.O. Molecular mechanisms of androgen action - a historical perspective. Methods Mol. Biol. 2011;776:3-24.
  2. Dohle G.R., Aver S., Bettocchi C. et al. Guidelines om Male Hypogonadism. In: EAU Guidelines, edition presented at the 27th EAU Annual Congress, Paris 2012. ISBN-13: 978-90-79754-99-1.
  3. Shores M.M., Matsumoto A.M., Sloan K.L. et al. Low serum testosterone and mortality in male veterans. Arch. Intern. Med. 2006; 166(15):1660—1665.
  4. Nieschlag E., Behre H., Nieschlag S. Testosterone: action, deficiency, substitution. Cambridge: Cambridge University Press, 2004.
  5. Wang C., Nieschlag E., Swerdloff R. et al. Investigation, treatment and monitoring of late-onset hypogonadism in males. ISA, ISSAM, EAU, EAA, and ASA recommendations. Eur. Urol. 2009;55:121 — 130.
  6. Kaufman J.M., Vermeulen A. The decline of androgen levels in elderly men and its clinical and therapeutic implications. Endocr. Rev. 2005 26(6):833—876.
  7. Haring R., Völzke H., Steveling A. et al. Low serum testosterone levels are associated with increased risk of mortality in a population-based cohort of men aged 20—79. Eur. Heart. J. 2010;31(12): 1494—1501.
  8. Корнеев И.А. Достоверность методов оценки уровня тестостерона и резистентность андрогеновых рецепторов при диагностике возрастного дефицита андрогенов у мужчин. Андрология и генитальная хирургия. 2007;2:6—9.
  9. Corona G., Mannucci E., Ricca V. et al. The age-related decline of testosterone is associated with different specific symptoms and signs in patients with sexual dysfunction. Int. J. Androl. 2009; 32: 720—728.
  10. Mulligan T., Frick M.F., Zuraw Q.C. et al. Prevalence of hypogonadism in males aged at least 45 years: the HIM study. Int. J. Clin. Pract. 2006; 60(7):762—769.
  11. Köhler T. S., Kim J., Feia K. et al. Prevalence of androgen deficiency in men with erectile dysfunction. Urology. 2008;71(4):693—697.
  12. Корнеев И. А., Глазнева С. Ю. Дефицит тестостерона у мужчин с расстройствами мочеиспускания. Андрология и генитальная хирургия. 2007;4:36—38.
  13. Корнеев И.А. Возрастной андрогенный дефицит в практике врача-уролога. Лечащий врач. 2012;1:50—53.
  14. Gooren L.J., Behre H.M., Saad F. et al. Diagnosing and treating testosterone deficiency in different parts of the world. Results from global market research. Aging Male. 2007; 10(4): 173—181.
  15. Hall S.A., Esche G.R., Araujo A.B. et al. Correlates of low testosterone and symptomatic androgen deficiency in a population-based sample. J. Clin. Endocrinol. Metab. 2008;93(10):3870—3877.
  16. Корнеев И.А., Глазнева С.Ю., Зассеев Р.Д. и др. Алгоритм диагностики возрастного андрогенного дефицита у мужчин с расстройствами мочеиспускания. Нефрология. 2011;2(15): 65—69.
  17. Morley J.E., Charlton E., Patrick P. et al. Validation of a screening questionnaire for androgen deficiency in aging males. Metabolism. 2000;49(9):1239—1242.
  18. Moore C., Huebler D., Zimmerman T. et al. The Aging Males’ Symptoms scale (AMS) as outcome measure for treatment of androgen deficiency. Eur. Urol. 2004;46(1):80—87.
  19. Wu F.C., Tajar A., Beynon J.M. et al; EMAS Group. Identification of late-onset hypogonadism in middle-aged and elderly men. N. Engl. J. Med. 2010; 363(2):123—135.
  20. Dobs A. S., Few W. L. 3rd, Blackman M. R. et al. Serum hormones in men with human immunodeficiency virus-associated wasting. J. Clin. Endocrinol. Metab. 1996; 81(11): 4108—4112.
  21. Reid I.R. Serum testosterone levels during chronic glucocorticoid therapy. Ann. Intern. Med. 1987;106(4):639-640.
  22. Diver M.J., Imtiaz K.E., Ahmad A.M. et al. Diurnal rhythms of serum total, free and bioavailable testosterone and of SHBG in middle-aged men compared with those in young men. Clin. Endocrinol. (Oxf). 2003;58:710-717.
  23. Bhasin S., Pencina M., Jasuja G.K. et al. Reference ranges for testosterone in men generated using liquid chromatography tandem mass spectrometry in a community-based sample of healthy nonobese young men in the Framingham Heart Study and applied to three geographically distinct cohorts. J. Clin. Endocrinol. Metab. 2011;96(8):2430-2439.
  24. Vermeulen A., Verdonck L., Kaufman J. M. A critical evaluation of simple methods for the estimation of free testosterone in serum. J. Clin. Endocrinol. Metab. 1999; 84(10):3666-3672.
  25. Zitzmann M., Faber S., Nieschlag E. Association of Specific Symptoms and Metabolic Risks with Serum Testosterone in Older Men. J. Clin. Endocrinol. Metabol. 2006; 91(11):4335-4343.
  26. Giltay E.J., Tishova Y.A., Mskhalaya G.J. et al. Effects of testosterone supplementation on depressive symptoms and sexual dysfunction in men with metabolic syndrome. J. Sex. Med. 2010; 7(7): 2572-2582.
  27. Zitzmann M., Weckesser M., Schoner O. et al. Changes in cerebral glucose metabolism and visuospatial capability in hypogonadal males under testosterone substitution therapy. Exp. Clin. Endocrinol. Diabetes. 2001; 109(5)302-304.
  28. Giltay E.J., Tishova Y.A., Mskhalaya G.J. et al. Effects of testosterone supplementation on depressive symptoms and sexual dysfunction in men with metabolic syndrome. J. Sex. Med. 2010;7(7):2572-2582.
  29. Moon du G., Park M. G., Lee S. W. et al. The efficacy and safety of testosterone undecanoate (Nebido®) in testosterone deficiency syndrome in Korean: a multicenter prospective study. J. Sex. Med. 2010; 7(6):2253-2260.
  30. Saad F., Aversa A., Isidori A. M. et al. Onset of effects of testosterone treatment and time span untilmaximum effects are achieved. Eur. J. Endocr. 2011;165(5):675-685.
  31. Yassin A., Saad F. Treatment of sexual dysfunction of hypogonadal patients with long-acting testosterone undecanoate (Nebido). World J. Urol. 2006;24(6):639—644.
  32. Corona G., Maggi M. The role of testosterone in erectile dysfunction. Nat. Rev. Urol. 2010;7(1):46-56.
  33. Saad F., Aversa A., Isidori A.M. et al. Onset of effects of testosterone treatment and time span until maximum effects are achieved. Eur. J. Endocr. 2011;165(5) 675-685.
  34. Tracz M. J., Sideras K., Bolona E. R. et al. Testosterone use in men and its effects on bone health. A systematic review and meta-analysis of randomized placebo-controlled trials. J. Clin. Endocrinol. Metab. 2006; 91(6):2011—2016.
  35. Kapoor D., Goodwin E., Channer K.S. et al. Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes. Eur. J. Endocrinol. 2006;154(6):899-906.
  36. Saad F., Gooren L., Haider A. et al. An exploratory study of the effect of 12 months administration of the novel long-acting testosterone undecanoate on measures of sexual function and the metabolic syndrome. Arch. Androl. 2007;53(6):353-357.
  37. Haider A., Gooren L.J., Padungton P. et al. Improvement of the metabolic syndrome and of nonalcoholic liver steatosis upon treatment of hypogonadal elderly men with parenteral testosterone undecanoate. Exp. Clin. Endocrinol. Diabetes. 2010;118(3):167—171.
  38. Shores M.M., Smith N.L., Forsberg C.W. et al. Testosterone Treatment Is Associated with Reduced Mortality in Men with Low Serum Testosterone Levels. Endocr. Rev. 2011; 32: 770-772.
  39. Stattin P., Lumme S., Tenkanen L., et al. High levels of circulating testosterone are not associated with increased prostate cancer risk; a pooled prospective study. Int. J. Cancer. 2004; 108(3): 418-424.
  40. Severi G., Morris H.A., MacInnis R.J. et al. Circulating steroid hormones and the risk of prostate cancer. Cancer Epidemiol. Biomarkers Prev. 2006; 15(1): 86-91.
  41. Shabsigh R., Crawford E.D., Nehra A. et al. Testosterone therapy in hypogonadal men and potential prostate cancer risk: a systematic review. Int. J. Impot. Res. 2009; 21(1): 9-23.
  42. Marks L.S., Mazer N.A., Mostaghel E. et al. Effect of testosterone replacement therapy on prostate tissue in men with late onset hypogonadism: a randomized controlled trial. JAMA. 2006;296(19):2351-2361.
  43. Fernández-Balsells M.M., Murad M.H., Lane M. et al. Adverse effects of testosterone therapy in adult men: a systematic review and meta-analysis. J. Clin. Endocrinol. Metab. 2010;95(6):2560-2575.
  44. Feneley M.R., Carruters M. Is testosterone treatment goog for the prostate? Study of safety during long-term treatment. J. Sex. Med. 2012; doi: 10.1111/j.1743-6109.2012.02808.x. [Epub ahead of print]
  45. Zitzmann M., Hanisch J. U., Mattern A. et al. IPASS Nebido: Final results from the largest international trial in testosterone substitution. A presentation to the Men’s Health World Congress. 2010.
  46. Kalinchenko S., Vishnevski E.L., Koval A.N. et al. Beneficial effects of testosterone administration on symptoms of the lower urinary tract in men with late-onset hypogonadism: a pilot study. Aging Male. 2008;11(2):57—61.
  47. Shigehara K., Namiki M. Late-onset hypogonadism syndrome and lower urinary tract symptoms. Korean J. Urol. 2011; 52(10):657—653.
  48. Morgentaler A., Morales A. Should hypogonadal men with prostate cancer receive testosterone? J. Urol. 2010;184(4):1257—1260.
  49. Sarodsy M. F. Testosterone replacement for hypogonadism after treatment of early prostate cancer with brachitherapy. Cancer. 2007;109(3):536—541.
  50. Jannini E.A., Gravina G.L., Morgentaler A. et al. Is testosterone a friend or a foe of the prostate? J. Sex. Med. 2011; 8(4): 946-955.
  51. Morgentaler A., Lipshultz L.I., Bennett R. et al. Testosterone therapy in men with untreated prostate cancer. J. Urol. 2011;195:1256-1261.
  52. Morgentaler A., Traish A.M. Shifting the paradigm of testosterone and prostate cancer: the saturation model and the limits of androgen-dependent growth. Eur. Urol. 2009;55(2):310-320.
  53. Morris M.J., Huang D., Kelly W.K. et al. Phase 1 trial of high-dose exogenous testosterone in patients with castration-resistant metastatic prostate cancer. Eur. Urol. 2009; 56(2):237-244.
  54. Haddad R.M., Kennedy C.C., Caples S.M. et al. Testosterone and cardiovascular risk in men: a systematic review and meta-analysis of randomized placebo-controlled trials. Mayo Clin. Proc. 2007; 82(1):29-39.
  55. Basaria S., Coviello A.D., Travison T.G. et al. Adverse event associated with testosterone administration. New Engl. J. Med. 2010;363(2):109-122.
  56. Raynaud J.P. Testosterone deficiency syndrome: Treatment and cancer risk. J. Steroid Biochem. Mol. Biol. 2009; 114(1—2):96—105.
  57. Calof O. M., Singh A. B., Lee M. L. et al. Adverse events associated with testosterone replacement in middle-aged and older men: a meta-analysis of randomized, placebo-controlled trials. J. Gerontol. A Biol. Sci. Med. Sci. 2005;60(11):1451—1457.
  58. Bashin S., Bremner W. J. Emerging issues in androgen replacement therapy. J. Clin. Endocrinol. Metab. 1997;82(1):3—8.
  59. Jockenhovel F., Vogel E., Kreutzer M. et al. Pharmacokinetics and pharmacodynamics of subcutaneous testosterone implants in hypogonadal men. Clin. Endocrinol. 1996;45(1):61—71.
  60. Salhenian B., Wang C., Alexander G. et al. Pharmacokinetics, bioefficacy and safety of sublingual testosterone cyclodextrin in hypogonadal men: comparison to testosterone enanthate — a clinical research center study. J. Clin. Endocrinol. Metab. 1995;80(12):3567—3575.
  61. Wang C., Swerdloff R., Kipnes M. et al. New testosterone buccal system (Striant) delivers physiological testosterone levels: pharmacokinetics study in hypogonadal men. J. Clin. Endocrinol. Metab. 2004; 89(8):3821—3829.
  62. Swerdloff R.S., Wang C. Transdermal androgens: pharmacology and applicability to hypogonadal elderly men. J. Endocrinol. Invest. 2005; 28(3):112—116.
  63. Bhasin S., Cunningham G.R., Hayes F.J. et al. Testosterone therapy in adult men with androgen deficiency syndromes: an endocrine society clinical practice guideline. J. Clin. Endocrinol. Metab. 2006;91(6):1995—2010.
  64. Zitzman M., Nieschlag E. Androgen receptor gene CAG repeat length and body mass index modulate the safety of long-term intramuscolar testosterone undecanoate therapy in hipogonadal men. J. Clin. Endocrinol. Metab. 2007; 92(10):3844—3853.
  65. Bassil N., Alkaade S., Morley J.E. The benefits and risks of testosterone replacement therapy: a review. Ther. Clin. Risk Manag. 2009; 5(3):427—448.
  66. Bhasin S., Pencina M., Jasuja G.K. et al. Reference ranges for testosterone in men generated using liquid chromatography tandem mass spectrometry in a community-based sample of healthy nonobese young men in the Framingham Heart Study and applied to three geographically distinct cohorts. J. Clin. Endocrinol. Metab. 2011; 96(8): 2430—2439.
  67. Palacios A., Campfield L.A., McClure R.D. et al. Effect of testosterone enanthate on hematopoiesis in normal men. Fertil. Steril. 1983;40(1):100—104.
  68. Khera M. Androgen replacement therapy after cancer treatment. Curr. Urol. Rep. 2010;11:393—399.
  69. Saad F., Gooren L., Haider A., Yassin A. An exploratory study of the effects of 12 month administration of the novel long-acting testosterone undecanoate on measures of sexual function and the metabolic syndrome. Arch. Androl. 2007;53(6):353—357.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2012 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies